Note: TCGX Acquisition Corp. II is offering only stock in its SPAC IPO. A typical SPAC IPO consists of units, with each unit made up of a share of stock plus a warrant or a right, or a fraction of a warrant or a right – or both – with the right to receive a share or a fractional share of stock conveyed upon the completion of the initial business combinaton.

(Incorporated in the Cayman Islands)

We are a newly organized blank check company. We intend to focus our search for a suitable acquisition target on companies in the life sciences and medical technology sectors. We may pursue a target company in Asia,  including Hong Kong and/or the People’s Republic of China.

Chen Yu, M.D., M.B.A., 52, has served as our CEO and as a director since our inception. Dr. Yu is the founder and Managing Member at TCGX, which was founded in January 2021, and has more than two decades of experience in healthcare investing, company building and operations. Prior to founding TCGX, Dr. Yu spent 16 years as a Managing Partner at Vivo Capital LLC.

Craig Skaling, 50, has served as our CFO and as a director since our inception. Mr. Skaling has more than 25 years of experience in finance, accounting, operations and compliance within the alternative asset management industry. He also serves as Chief Financial Officer and Chief Operating Officer of TCGX, which he joined in February 2022, and as a director of TCGX Asia Life Sciences Partners I, Ltd. since May 2026. Prior to joining TCGX, Mr. Skaling served as Director of Finance at Vetamer Capital Management, a registered investment advisor, from November 2020 to February 2022, investing in both public and private financial technology companies.

(Note: TCGX Acquisition Corp. II filed its S-1 on Sept. 25, 2026, for its SPAC IPO consisting of 10 million shares at $10.00 each to raise $100 million.)